Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Unicycive Therapeutics to post earnings of ($0.13) per share for the quarter.
Unicycive Therapeutics Stock Down 1.2 %
NASDAQ UNCY opened at $0.64 on Wednesday. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.60. The firm has a 50-day moving average price of $0.59 and a 200 day moving average price of $0.56. The stock has a market capitalization of $65.97 million, a P/E ratio of -0.66 and a beta of 2.26.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Unicycive Therapeutics in a report on Wednesday, January 29th.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Further Reading
- Five stocks we like better than Unicycive Therapeutics
- Market Cap Calculator: How to Calculate Market Cap
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- What is Forex and How Does it Work?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Which Wall Street Analysts are the Most Accurate?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
